The level of NT-proBNP in ambulatory patients with chronic heart failure with preserved ejection fraction of the left ventricle


Cite item

Full Text

Abstract

The prevalence of chronic heart failure (CHF) remains high. Echocardiography is a reliable method of diagnosing heart failure. Determination of brain natriuretic peptide allows to identify patients with the most probable diagnosis of heart failure, which requires further instrumental examination of patients. Aim. To study the level of the brain natriuretic peptide in patients with diastolic chronic heart failure with preserved left ventricular ejection fraction. Materials and methods. The study included 96 outpatients with diastolic chronic heart failure I-III functional class with a preserved left ventricular ejection fraction at the age of 65.06 ± 1.15 years and 50 practically healthy people aged 39.90 ± 1.64 years as a control group who underwent a preventive examination. The level of the N-terminal fragment of the medullary natriuretic peptide (NT-proBNP) in serum was determined using a test system (Vector-Best, Russia). Results. The concentration of NT-proBNP in patients with diastolic heart failure with a preserved left ventricular ejection fraction was 108.18 ± 21.64 in the range from 0.0 to 1212.3 pg/ml compared to the control of 7.6 ± 1.38 pg/ml, p<0.05. A positive correlation was found between the concentration of NT-proBNP and the area of the left atrium (r=0.35), left ventricular E/e '(r=0.6), and left ventricular end-systolic volume (r=0.48). The level of NT-proBNP had no correlation with the functional class of CHF (r=0,23), as well as with the stage of CHF (r=0,23). Conclusions. Thus, patients with diastolic CHF with a preserved ejection fraction in 67% of cases had a level of NT-proBNP in the blood less than the diagnostic threshold. The concentration of NT-proBNP in the serum positively correlates with increased pressure in the cavity of the left ventricle, the end-systolic volume in it and the area of the left atrium.

About the authors

V V Kirillova

Ural state medical University; Institute for medical cell technologies; Medical Center Ural, Department of the early diagnostic and treatment of chronic heart failure

Email: venova@list.ru
к.м.н., с.н.с. лаб. антивозрастных технологий ГАУЗ СО «Институт медицинских клеточных технологий»; ассистент каф. биохимии ФГБОУ ВО УГМУ Минздрава РФ; зав. отд. ранней диагностики и лечения хронической сердечной недостаточности ООО Клиника «Уральская», ORCID 0000-0001-6254-0756 Yekaterinburg, Russia

L A Sokolova

Ural state medical University; Medical Center Ural, Department of the early diagnostic and treatment of chronic heart failure

д.м.н., проф., зав. каф. скорой медицинской помощи ФГБОУ ВО УГМУ Минздрава РФ; директор ООО Клиника «Уральская» Yekaterinburg, Russia

V N Meshchaninov

Ural state medical University; Institute for medical cell technologies

д.м.н., проф., г.н.с., зав. лаб. антивозрастных технологий ГАУЗ СО «Институт медицинских клеточных технологий»; зав. каф. биохимии ФГБОУ ВО УГМУ Минздрава РФ Yekaterinburg, Russia

V I Pershanova

Medical Center Ural, Department of the early diagnostic and treatment of chronic heart failure

врач клинико-диагностической лаборатории ООО Клиника «Уральская» Yekaterinburg, Russia

References

  1. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;8(136):7-13 doi:10.15829/ 1560-4071-2016-8-7-13
  2. Paulus W.J, Tschope C, Sanderson J.E, Rusconi C, Flachskampf F.A, Rademakers F.E, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539-50. doi: 10.1093/eurheartj/ehm037
  3. Caballero L, Kou S, Dulgheru R, Gonjilashvili N, Athanassopoulos G.D, Barone D, et al. Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study. Eur Heart J Cardiovasc Imaging. 2015;16:1031-41. doi: 10.1093/ehjci/jev083
  4. Lang M, Badano L.P, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233-70. doi: 10.1016/j.echo.2014.10.003
  5. Maisel A, Krishnaswamy P, Nowak R, Mc Cord J, Hollander J.E, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-7. doi: 10.1056/NEJMoa020233
  6. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402-12. doi: 10.1172/JCI115146
  7. Hunt P.J, Yandle T.G, Nicholls M.G Richards A.M, Espiner E.A. The amino - terminal portion of pro - brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun. 1995;214:1175-83. doi: 10.1006/bbrc.1995.2410
  8. Ponikowski P, Voors A.A, Anker S.D, Bueno H, Cleland J.G, Coats A.J, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart J. 2016;37(27):2129-200. doi: 10.1093/eurheartj/ehw128
  9. Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л., Беленков Ю.Н. и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Сердечная Недостаточность. 2017;18(1):3-40 doi: 10.18087/rhfj.2017.1.2346
  10. Maisel A, Mueller C, Adams K, Anker S.D, Aspromonte N, Cleland J.G.F, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824-39. doi: 10.1016/j.ejheart.2008.07.014
  11. Wilson Tang W.H, Girod J.P, Lee M.J, Starling R.C, Young J.B, Van Lente F. Plasma B-Type Natriuretic Peptide Levels in Ambulatory Patients With Established Chronic Symptomatic Systolic. Heart Failure Circulation. 2003;108:2964-6. doi: 10.1161/01.CIR.0000106903. 98196.B6
  12. Santosa Y.P, Tjandrawati A, Noormartany, Erwinanto, Yahya A.F, Martanto E, et al. Comparison of Pro B-natriuretic Peptide in Hypertensive Patients with and without Diastolic Dysfunction. Acta Med Indones. 2008;40(1):19-23.
  13. Knebel F, Eddicks S, Schimke I, Bierbaum M, Schattke S, Beling M, et al. Myocardial tissue Doppler echocardiography and N-terminal B-type natriuretic peptide (NT-proBNP) in diastolic and systolic heart failure. Cardiobvasc Ultrasoud. 2008;6:45. doi: 10.1186/1476-7120-6-45
  14. Maisel A, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point - of - care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141(3):367-74. doi:10.1067/ mhj.2001.113215
  15. Nagueh S.F, Smiseth O.A, Appleton C.P, Byrd B.F 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17(12):1321-60. doi: 10.1093/ehjci/jew082
  16. Ommen S.R, Nishimura R.A, Appleton C.P, Miller F.A, Oh J.K, Redfield M.M, et al. Clinical utility of doppler echocardiography and tissue doppler imaging in the estimation of left ventricular filling pressures. A comparative simultaneous doppler - catheterization Study. Circulation. 2000;102:1788-94.
  17. Hung T.C, Wang K.T, Yun C.H, Kuo J.Y, Hou C.J, Liu C.Y, et al. Value of serum N-terminal B-type natriuretic peptide in asymptomatic structural heart disease in Taiwanese population: Comparisons with current ESC Guidelines. Int J Cardiol. 2017;231:195-200. doi: 10.1016/j.ijcard.2016.12.180
  18. Подзолков В.И., Тарзиманова А.И., Лория И.Ж. Изменение уровня натрийуретических пептидов у пациентов с фибрилляцией предсердий при лечении антиаритмическими препаратами. Рациональная фармакотерапия в кардиологии. 2015;11(4):365-70
  19. Ellinor P.T, Low A.F, Patton K.K, et al. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in atrial fibrillation. J Am Coll Cardiol. 2005;45:82-6. doi: 10.1016/j.jacc.2004.09.045

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies